In this review, we summarize the clinical, molecular, and emerging pathological insights into NDPACX and propose that targeting endolysosomal homeostasis may open new therapeutic avenues for both hereditary and idiopathic neurodegenerative diseases characterized by proteinopathies. This evidence concerns the gene SLC9A6 and proteostasis deficiencies.